DUO-O: A randomized phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients.

Philipp Harter,Mariusz Bidziński,Nicoletta Colombo,Anne Floquet,María Jesús Rubio Pérez,Jae Weon Kim,Stephanie Lheureux,Christian Marth,Gitte-Bettina Nyvang,Aikou Okamoto,Alexander Reuss,Giovanni Scambia,Fabian Trillsch,Mehmet Ali Vardar,Els Van Nieuwenhuysen,Jasmine Lichfield,Paul Rugman,Philip Twumasi-Ankrah,Carol Aghajanian

DUO-O: A randomized phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients.

2019

Philipp Harter
Mariusz Bidziński
Nicoletta Colombo
Anne Floquet
María Jesús Rubio Pérez
Jae Weon Kim
Stephanie Lheureux
Christian Marth
Gitte-Bettina Nyvang
Aikou Okamoto
Alexander Reuss
Giovanni Scambia
Fabian Trillsch
Mehmet Ali Vardar
Els Van Nieuwenhuysen
Jasmine Lichfield
Paul Rugman
Philip Twumasi-Ankrah
Carol Aghajanian

TPS5598Background: Ovarian cancer (OC) is the leading cause of death from gynecologic cancers in US women. Despite high response rates to first-line treatment, ~70% of patients (pts) relapse within...

Keywords:

Durvalumab
Olaparib
Bevacizumab
Ovarian cancer
Oncology
Pathology
Internal medicine
Chemotherapy
Medicine
advanced ovarian cancer
newly diagnosed
Cause of death

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations